Cedars-Sinai Rheumatology Experts Present Latest Research at ACR Convergence 2023
Highlights: Racial Differences in the Severity of Scleroderma, Harnessing Laser Capture Technology to Understand Skin Hardening, and Pinpointing Heart Disease Risk in Women With Lupus
Physicians and scientists from the Kao Autoimmunity Institute will be among Cedars-Sinai experts presenting at ACR Convergence 2023, the premier conference of the American College of Rheumatology. The scientific meeting will be held Nov. 10-15 in San Diego, California.
Cedars-Sinai investigators will share research findings designed to improve the prevention, diagnosis and treatment of rheumatic diseases, which affect nearly 60 million adults in the U.S.
On Saturday, Nov. 11, Daniel Wallace, MD, associate director of the Rheumatology Fellowship Program at Cedars-Sinai, will receive the Distinguished Clinician Scholar Award. The American College of Rheumatology gives the honor to a rheumatologist who has made outstanding contributions in clinical medicine, clinical scholarship or education.
Cedars-Sinai Presentations
Racial Variability in Immune Responses Only Partially Explains Differential Systemic Sclerosis Disease Severity
Francesco Boin, MD, chair of Rheumatology and director of the Cedars-Sinai Kao Multispecialty Scleroderma Program
- Largest systematic analysis of autoantibody responses sheds light on why Black people with scleroderma may have more severe disease presentation than white patients.
Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma
Irene Choi, MS, Francesco Boin, MD and Nunzio Bottini, MD, PhD, director of the Kao Autoimmunity Institute
- Laser-assisted microscopy technology improves understanding of the complex structure of skin affected by fibrosis and may pave the way to new therapeutics for scleroderma patients.
Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)
Audrey Hagiwara, MD, Mariko Ishimori, MD, and Caroline Jefferies, PhD
- Among women with lupus and chest pain but no diagnosis of coronary artery disease, 40% did have undiagnosed coronary microvascular dysfunction.
Cumulative Infections by Week 52 Among Patients With SLE: A Summary of Data From Placebo-Controlled Belimumab Studies
Daniel Wallace, MD
- Findings further support the favorable safety profile of belimumab for the treatment of systemic lupus erythematosus (SLE).
Circulating CTHRC1 Levels Are Associated With Disease Severity and Predict Survival in Systemic Sclerosis
Francesco Boin, MD
- Circulating CTHRC1 levels are increased in systemic sclerosis patients and exhibit a significant association with more severe skin disease, pulmonary arterial hypertension and worse survival.
Single Cell RNA-seq of Myeloid Cells From Systemic Sclerosis Patients Identifies Circulating Monocyte Population With Interferon Signature Associated With ILD
Richard Ainsworth, PhD, Nunzio Bottini, MD, PhD, and Francesco Boin, MD
- Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). Investigators identified features of circulating immune cells associated with SSc-ILD, which could lead to the development of biomarkers and treatment targets of the disease.
NOTE: A full list of Cedars-Sinai’s research presentations at the conference is available upon request.
Expert Interviews Available
During the conference, Cedars-Sinai rheumatology experts are available to comment on research they have presented as well as a wide variety of clinical and scientific topics in the field of rheumatic diseases and patient care. For interviews, please contact Cedars-Sinai Communications Specialist Laura Coverson by phone, at 310-562-1112, or by email: Laura.Coverson@cshs.org.